Articles and Features - Triferic
Medical Director Highlights Clinical and Economic Benefits with Triferic

March 2018

Anemia Connection

Welcome to Your Anemia Connection! Click below to read our recent eNewsletter and see the key benefits of Triferic and Anemia Management.

We, along with AAKP, created an Anemia brochure that explains the side effects & the various treatment options, which include Triferic.
Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis

Seminars in Nephrology | March 2016

Read the featured article in the September issue
See our featured article and ad in the August issue of the DPC Kidney Citizen newsletter (on pages 8-9)
Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis

Dialysate FPC iron is a novel option for iron replacement in patients receiving hemodialysis. There are potential advantages compared to IV iron injection. In particular, the quantitative matching of iron losses and replacement are more physiologic with dialysate FPC. The slower delivery rates may help to avoid oxidative stress and other potential safety issues with IV iron treatment.

Triferic Pharmacokinetics Characterized

Triferic (ferric pyrophosphate citrate) administered during dialysis or intravenously rapidly donates iron to transferrin and is cleared quickly from the circulation, according to new findings presented at the National Kidney Foundation’s 2017 Spring Clinical Meetings.

Practical Approaches to Iron Therapy
How ‘Bundling’ Changed Dialysis Care

Introduction of the federal government’s prospective payment system for dialysis care (“bundling”) in January 1, 2011 has brought about a new frugality and cost-consciousness in the use of medications and other resources in the management of patients with end-stage renal disease (ESRD). Dialysis providers were now being challenged to control costs—especially those associated with medications—while providing quality care.

Triferic®—A Unique Iron Replacement that Maintains Hemoglobin

During Kidney Week 2016, Robert L. Chioini, founder, chairman, and chief executive officer of Rockwell Medical presented an overview of Triferic®, the only FDA-approved drug indicated to replace iron at every dialysis treatment and maintain hemoglobin in adult patients with chronic kidney disease (CKD) on a regimen of regular hemodialysis. Triferic (ferric pyrophosphate citrate) was highlighted during an Exhibitor Spotlight at the American Society of Nephrology Kidney Week in Chicago, Illinois.

Share this page: